How Revolve Group (RVLV) is introducing Wall Street to FashTech
For Immediate Release – June 10th, 2019
Short-Term Price Target $50 and “beyond”
Citron has never commented on an IPO, but sometimes as an investor you read something so compelling you have to share. In this case it is the S-1 filing for Revolve Group. Citron tweeted as Revolve opened for trading at $27 as we think the stock will hit $50 as soon as investors read the S-1 and understands how Revolve has revolutionized Fashtech.
Even the harshest skeptic cannot help but be impressed at the abundance of data supplied by Revolve in their IPO prospectus that illustrate more impressive unit economics than we have seen from any e-commerce IPO.
Revolve – The business is as beautiful as the models
For those who don’t know, Revolve is the leading online destination targeted towards millennial consumers seeking premium fashion. Citron is excited that we get to highlight this business before any sell side research has a chance to opine.
Even the most cynical short or market critic can’t help but be impressed and awed at what Revolve has built and its future prospects.
Without further editorial… below are what we believe to be some of the KPI’s that make the business as sexy as the pictures.
Citron 2019 / 2018 Reports
How Revolve Group (RVLV) is introducing Wall Street to FashTech
FLEETCOR Citron Exposes one of the Largest Clean Energy Frauds in US History
Jumia – Indisputable Evidence of Fraud
JMIA needs to be Halted…Citron’s final word on why Jumia is a worthless FRAUD
Not All IPOs are Created Equal Jumia is a Fraud
Amedisys – The Most Vulnerable Name in Healthcare
Village Farms – Will the SEC Halt this Pump & Dump
LYFT The Amateur Short
Shopify – What a Difference a Month Makes
The poster child for Institutionalized Academic Cheating
Citron Exposes Elder Abuse Within Inogen’s Sale Tactics Price Target $46
What a Difference a Month Makes $TWTR will be A-OK with AOC
RH The Most Compelling Story in Retail
Citron Publishes the Smoking Gun on Ligand Pharmaceuticals
Citron Research Backing Up the Sleigh on Facebook
Twitter has become the Harvey Weinstein of Social Media
Everything Has Changed: The Big 5 Canadian Cannabis Companies Have Achieved “Platform Status”
At What Point Is MNK Selective Disclosure Complete Fraud?
NIO short is a Tesla Déjà vu – Path to $12 Should Have Little Resistance
Wayfair Has Become a Case study in Diseconomies of Scale
Citron reverses opinion on Tesla
Long Pyxus International (NYSE:PYX) – Short-Term Price Target of $65
Namaste: Citron has exposed complete FRAUD that underpins the ‘Business’ of Namaste.
Namaste A Party Not to Sell Your Shares
Our Final Word on $TLRY before $50
Cronos The Dark Side of The Cannabis Space
Wayfair: Citron is listening to the smartest guys in the room
Nvidia- The Dog that Finally Caught the Car
Tilray – Next in line in a Budding Cannabis Industry
$TWTR Just Made the Turn and Is Hitting Stride
Citron Research Explains Why AbbVie is on its way to $60.
Citron Exposes History of FRAUD Behind PolarityTE
Citron expects Netflix to dip back to $340
Fitbit: From Fad to Future
Citron Research Initiates Coverage on Snap Inc. Target Price $17
Citron Changes our Position on ROKU
Inogen Needs to Take a Breath
Citron Research is Bullish on the Most Shorted Stock in the World.
Hailiang Education- China Hustle Déjà vu
Wayfair is Growing Enemies Faster than Customers
Wait til the Senate Hears Twitter’s Hidden Secret
Shopify has a BIG Facebook Problem!
Exact Sciences Corp: We admit to being early. But the science won’t be held back.
Citron 2017 & 2016 Report Archives
2017 Reports
2016 Reports
